跳至主要内容
临床试验/NCT00126061
NCT00126061已完成3 期

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Intravenous Tedisamil Sesquifumarate in the Rapid Conversion to Normal Sinus Rhythm in Male Subjects With Recent Onset Atrial Fibrillation or Flutter

Solvay Pharmaceuticals41 个研究点 分布在 7 个国家开始时间: 2004年10月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
试验地点
41

研究概览

简要总结

The purpose of this study is to demonstrate the ability of tedisamil to convert atrial fibrillation or flutter into normal sinus rhythm (NSR) in male patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Willing to sign informed consent before screening examinations are performed and before the study drug is administered
  • Males > 18 years of age
  • Subjects with documented (60 second rhythm strip) symptomatic atrial fibrillation or flutter (duration > 3 hours and < 45 days) at the time of randomization
  • Subjects who are in no distress and hemodynamically stable (supine systolic blood pressure > 90 mmHg and diastolic blood pressure < 105 mmHg)

排除标准

  • Acute myocardial infarction and cerebrovascular accidents
  • Coronary and heart failure symptoms
  • Life-threatening ventricular arrhythmias and electrocardiogram (ECG) abnormalities
  • Electrolyte abnormalities
  • Concurrent antiarrhythmic treatments

研究者

申办方类型
Industry

研究点 (41)

Loading locations...

相似试验